Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Role and rationale of gene therapy and other novel therapies in the management of NMIBC

(2009) Carlos Lojo Rial et al.   Expert Review of Anticancer Therapy

Generation of Monoclonal Antibody Targeting Fibroblast Growth Factor Receptor 3

(2009) Olena Gorbenko et al.   HYBRIDOMA

Consistent genomic alterations in carcinomain situof the urinary bladder confirm the presence of two major pathways in bladder cancer development

(2009) Karsten Zieger et al.   INTERNATIONAL JOURNAL OF CANCER

Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction

(2009) Shambhunath Choudhary et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

(2009) Jing Qing et al.   JOURNAL OF CLINICAL INVESTIGATION

Activation of RAS Family Genes in Urothelial Carcinoma

(2009) I. Boulalas et al.   JOURNAL OF UROLOGY

FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations

(2009) Sarah Lott et al.   MODERN PATHOLOGY

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

(2008) Maximilian Burger et al.   EUROPEAN UROLOGY

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

(2008) Louis S. Pymar et al.   HUMAN MOLECULAR GENETICS

Loss of heterozygosity at 9q32–33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium

(2008) A Lopez-Beltran et al.   JOURNAL OF PATHOLOGY

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

(2008) J. L. Martinez-Torrecuadrada et al.   MOLECULAR CANCER THERAPEUTICS

Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur

(2007) Francesca Barbisan et al.   CANCER